Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FORA 
Forian Inc (FORA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: FORA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.11% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.38M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 1.03 | 52 Weeks Range 1.64 - 4.03 | Updated Date 11/4/2025 |
52 Weeks Range 1.64 - 4.03 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate 0.0137 | Actual - |
Profitability
Profit Margin -3.62% | Operating Margin (TTM) 0.62% |
Management Effectiveness
Return on Assets (TTM) -4.77% | Return on Equity (TTM) -3.2% |
Valuation
Trailing PE - | Forward PE 24.75 | Enterprise Value 40559434 | Price to Sales(TTM) 2.77 |
Enterprise Value 40559434 | Price to Sales(TTM) 2.77 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA 20.05 | Shares Outstanding 31112312 | Shares Floating 9121819 |
Shares Outstanding 31112312 | Shares Floating 9121819 | ||
Percent Insiders 51.91 | Percent Institutions 13 |
Upturn AI SWOT
Forian Inc
Company Overview
History and Background
Forian Inc. was formed through the combination of Helix Technologies, a provider of software and data analytics solutions to the cannabis industry, and Medical Marijuana, Inc. The goal was to create a leading provider of data-driven solutions and services for the cannabis and hemp industries and the healthcare sector. They focus on leveraging data and insights to optimize operations, improve patient outcomes, and drive revenue growth for their clients.
Core Business Areas
- Cannabis Data & Analytics: Provides data and analytics solutions tailored to the cannabis industry, helping businesses optimize their operations, marketing, and sales strategies.
- Healthcare Data Solutions: Offers data-driven solutions for healthcare providers and organizations, focusing on improving patient outcomes and operational efficiency.
Leadership and Structure
Forian Inc's leadership team includes experienced executives in the fields of data analytics, healthcare, and cannabis. The organizational structure is designed to support its core business areas and promote collaboration across departments.
Top Products and Market Share
Key Offerings
- Forian Insights: A data and analytics platform providing insights into cannabis market trends, consumer behavior, and regulatory changes. Market share data is challenging to pinpoint precisely due to the fragmented nature of the cannabis data market, but it aims to be a leading provider. Key competitors include New Frontier Data and BDSA. Revenue from insights is estimated to be a significant portion of their data analytics segment.
- Patient Outcomes Solutions: Data analytics services for healthcare, focusing on improved patient outcomes and operational efficiencies. Market share is difficult to accurately ascertain, but it competes with traditional healthcare data analytics firms like Optum and Cerner. Revenue contribution is substantial and growing as healthcare becomes more data-driven.
Market Dynamics
Industry Overview
The cannabis industry is experiencing rapid growth and increasing regulation, creating a high demand for data-driven insights. The healthcare sector is also undergoing a data revolution, with providers seeking ways to improve patient outcomes and reduce costs. Both markets are fragmented with intense competition
Positioning
Forian Inc aims to be a leading provider of data and analytics solutions in both the cannabis and healthcare industries, differentiating itself through a combination of industry expertise and advanced analytics capabilities.
Total Addressable Market (TAM)
The combined TAM for cannabis data analytics and healthcare data solutions is estimated to be billions of dollars. Forian is well-positioned to capture a substantial share of this market through its specialized expertise and comprehensive suite of solutions.
Upturn SWOT Analysis
Strengths
- Strong industry expertise in cannabis and healthcare
- Comprehensive data analytics platform
- Experienced leadership team
- Proprietary data assets
Weaknesses
- Limited financial resources compared to larger competitors
- Relatively small market share in competitive markets
- Dependence on regulatory changes in the cannabis industry
- Fluctuations in quarterly revenue
Opportunities
- Expanding into new geographic markets
- Developing new data analytics solutions
- Acquiring complementary businesses
- Forming strategic partnerships
Threats
- Increasing competition from larger data analytics firms
- Changes in cannabis regulations
- Economic downturn
- Data security breaches
Competitors and Market Share
Key Competitors
- MSCI
- IQVIA
- NEWR
- GDYN
Competitive Landscape
Forian Inc faces competition from larger, more established data analytics firms. However, it differentiates itself through its industry expertise and specialized solutions.
Major Acquisitions
Abattis Bioceuticals Corp
- Year: 2021
- Acquisition Price (USD millions): 3.25
- Strategic Rationale: Strengthened Forian's footprint in the healthcare data and analytics market and enabled the company to provide deeper data driven insights into healthcare
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic revenue growth.
Future Projections: Future growth is expected to be driven by continued expansion in the cannabis and healthcare data analytics markets. Analyst estimates vary depending on the company's ability to execute its growth strategy.
Recent Initiatives: Recent initiatives include new product launches, strategic partnerships, and expansion into new markets.
Summary
Forian Inc. aims to be a key player in the cannabis and healthcare data analytics spaces, but faces stiff competition from larger firms. Its growth trajectory depends on successfully navigating evolving regulations and expanding its market presence. Strategic partnerships and new product innovations are critical for future success. Forian needs to increase revenue and improve profit margins to strengthen its financial standing. The variability in revenue suggests they should try to find consistent revenue sources to maintain profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Reports
- Analyst Estimates
Disclaimers:
Data and analysis are based on available information and are subject to change. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Forian Inc
Exchange NASDAQ | Headquaters Newtown, PA, United States | ||
IPO Launch date 2021-03-03 | Co-Founder, CEO, President & Executive Chairman of the Board Mr. Max C. Wygod | ||
Sector Healthcare | Industry Health Information Services | Full time employees 47 | Website https://forian.com |
Full time employees 47 | Website https://forian.com | ||
Forian Inc. provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the life science, healthcare, and financial services industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions. The company's subscription and services-based solutions cover the life sciences, pharmaceutical services, healthcare payer, and provider and financial services industries. Forian Inc. was founded in 2020 and is headquartered in Newtown, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.